19
November

08:00 AM EST

Bioinformatics

Name: Drug Discovery Biology Strategy Meeting East Coast 2025 (Boston)
Start: 2025-11-19T08:00
End: 2025-11-19T18:00
Location: Crowne Plaza, London Docklands

&

Drug Discovery Biology

Strategy Meeting East Coast USA 2025

Pushing our understanding of the physiological context and quality of drug target characterisation, validation, and safety profiling throughout the preclinical space

Le Méridien Boston Cambridge

A MEETING EXPERIENCE UNLIKE ANY OTHER

Fresh Biology Insights

Tired of the same conference experience? Real discussions and genuine networking are often promised, but not always delivered. Proventa International’s R&D Strategy Meetings are designed to avoid the pitfalls of a typical conference, by providing the right environment to make those important connections through interactive roundtable discussions, exclusive networking and keynote panel debates. Join Biology professionals from across the East Coast, in Boston MA, to discover new insights and take your company’s mission to the next level.

What makes our strategy meetings unique?

Roundtable Discussions

Intimate discussions led by renowned industry experts. Have your voice heard and debate alongside like-minded life science executives.

Unrivalled Networking

With senior delegation from big pharma and innovative biotech from across the East Coast, you can network with peers from different locations, all in one place.

Personalised Agenda

Choose the topics that matter to you. Reserve your place at the roundtable discussions and ensure your whole day delivers the insights you need to hear.

Solutions to your Problems

We’ve partnered with the best solution providers to solve your biggest challenges. Engage in pre-arranged, private meetings to address your specific needs and find a tangible solution.

Industry Researched Topics

We guarantee our agenda is up-to-date and mission critical because its designed by you. We speak to our extended network of senior decision makers to ensure the most important topics are discussed.

Senior Decision Makers

The entire strategy meeting is specifically tailored to the needs and challenges of senior life science professionals. Discover how your peers are dealing with the same challenges as you.

Our Facilitators

Our panel of facilitators play a key role in shaping the agenda for the day. See who will be bringing their expertise to the table at our upcoming strategy meeting.

Aditya Ambade, Ph.D

Director Business Development Discovery Biology SAI Life Sciences

Ajita V. Singh, Ph.D

Associate Director, Discovery Biology SAI Life Sciences

Atli Thorarensen

Vice President, Head of Chemistry Cellarity

Bill Jackson, Ph.D

Founder & CEO Base Pair Biotechnologies, Inc.

Charles Sinclair

Vice President, Translation Sciences Pioneering Medicines

Christina Ansted

Senior Managing Partner RCP Venture Capital

Dan Rozelle

Vice President, Data Analytics Rancho Biosciences

David Sherris

CEO Attivare Therapeutics

Session – Next Generation OV and New Combinational Approaches for Treatment of Solid Tumors 
Dr. Sherris has over 30 years’ experience in translational medicine involving basic research, pharmaceutics and diagnostics.  Dr. Sherris has been a successful serial entrepreneur developing biotechnology companies from the ground up, devising corporate strategy, enacting programs and carrying companies through funding and acquisition.  Dr. Sherris prides himself as a “roll up your sleeves” CEO, entrepreneur, business development officer, drug developer and scientist, not simply a delegator. Dr. Sherris has worked with venture capital companies where he has both advised and raised finances for biotech companies.  Dr. Sherris has been employed by pharmaceutical and biotechnology companies to manage external (academic groups and contract research organizations) and internal (directly manage, augment and expand internal scientific programs) research and development. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas including oncology, ophthalmology, dermatology, neurology, gene therapy and infectious disease.  Dr. Sherris has held positions of increasing responsibility in public and private companies. Dr. Sherris has developed drugs from the bench to the clinic, partnered technologies to pharmaceutical companies and raised capital for companies at the triple digit million dollar levels.

Diane Joseph-McCarthy

Executive Director, Bioengineering Technology & Entrepreneurship Center Boston University

Eric Ma

Senior Principal Data Scientist Moderna

Fatemeh Mojtabai

Founder and CEO Novatarg Theranostics

Govinda Bhisetti

Vice President and Head of Computational Chemistry Cellarity

Huseyin Mehmet

Executive Director, New Ventures University of Massachusetts Medical School

Huseyin Mehmet is a drug hunter and research scientist with >35 years’ experience in basic and clinical academic research and in pharmaceutical / biotechnology drug discovery. He received his PhD from the Medical Research Council in the UJ and went on to work at University College London, the Imperial Cancer Research Fund (now Cancer Research UK), Cold Spring Harbor Lab, USA and then took a faculty position at Imperial College School of Medicine. There his work focused on cerebral hypoxic ischemic injury in neonates and he was part of the team that developed mild hypothermia for the treatment of birth asphyxia. In 2006 Huseyin left the UK to join Merck and Co, in the USA. He worked in biomarker discovery, target identification and several drug discovery programs up to clinical candidate selection. For the next few years, he took on roles with increasing responsibility in several biotech companies and also consulted for a number of start-up companies working with prominent VC firms (e.g. Atlas Ventures and Versant Ventures). Since 2021, Huseyin has led the New Ventures team in the BRIDGE Innovation and Business Development office at UMass Chan Medical School, where he is responsible for the scientific partnering of intellectual property arising from faculty discoveries.

Julia Fox

Director Takeda

Lakshmi Muthuswamy

Senior Director and Head, Computational Biology and Data Science Blueprint Medicines

Larry Mulcahy, Ph.D.

Product Manager, Biologics Revvity Signals

Lijuan Jiang

Vice President, DMPK & Bioanalysis Enanta Pharmaceuticals

Michael Janes

Co Founder – Chief Revenue Officer RCP Venture Capital

Mohamed Kassam

Head, Bioinformatics Zifo

Nathan McBride

Chief Information Officer Xilio Therapeutics, Inc.

Prasoon Chaturvedi

Vice President, Head of DMPK C4 Therapeutics, Inc.

Prateek Katti

Investor Newpath Partners

Richard Heidebrecht

Vice President of Research and Development Glycologix

Shengwen Zhang

Executive Director QLD Biotherapeutics

Zev Wisotsky

Director, Drug Discovery New Modality Solutions Revvity Signals

Winnie Tam

Scientific Director, Head of Precision Medicine Immunology Translation Research AbbVie

First name	Last name	Job title	Company name	Photo URL	Bio Position
Aditya	Ambade, Ph.D	Director Business Development Discovery Biology	SAI Life Sciences	https://proventainternational.com/wp-content/uploads/2025/10/Aditya-Ambade.jpg	Aditya has a Ph.D. in cancer biology, a post-doc from UMASS Med School and has over 15 years of experience in drug discovery. As director of business development, he leads strategic partnerships and drives growth across early-stage therapeutic innovation.
Ajita	V. Singh,	Associate Director, Discovery Biology	SAI Life Sciences	https://proventainternational.com/wp-content/uploads/2025/10/Ajita-V-Singh.jpg	Ajita V. Singh received a Ph.D.in Medicinal Chemistry and has over 18 years of experience in drug discovery. She completed her postdoctoral training at Dana Farber Cancer Institute and served as Faculty at Harvard. With more than 15peer-reviewed publications in high-impact journals, her experience spans a broad range of therapeutic areas, including oncology, immuno-oncology, women’s health, autoimmune diseases and rare diseases.
Atli	Thorarensen	Vice President, Head of Chemistry	Cellarity	https://proventainternational.com/wp-content/uploads/2022/06/Atli-Thorarensen-1.jpg	Atli Thorarensen is Vice President of chemistry at Cellarity. There he oversees medicinal chemistry DMPK and computational chemistry platform. His research interest includes use of advanced computational methods to accelerate medicinal chemistry in both lead identification as well as lead optimization. Prior to joining Cellarity he was at Pfizer as a medicinal chemist in various roles resulting in several clinical candidates such as Ritlecitinib. Atli holds a PhD in chemistry from University of Illinois Urbana-Champaign.
Bill	Jackson, Ph.D	Founder & CEO	Base Pair Biotechnologies, Inc.	https://proventainternational.com/wp-content/uploads/2024/11/Bill-Jackson-1.jpg	As CEO of BasePair Biotechnologies, Bill has been leading the development and commercialization of aptamer-based diagnostics and therapeutics since 2012. In addition to private capital, Dr. Jackson has also secured significant non-dilutive funding through government grants and contracts as well as revenue from earlystage products and services. He has served as principal investigator on more than 20 federally funded research projects and established collaborations with clinicians and researchers at world-class research institutions and universities. Bill also serves frequently as a panel reviewer regarding molecular diagnostics and related tools, environmental monitoring, and biodefense. His stated mission is to leverage the potential of aptamers to create innovative solutions for global health and environmental challenges, and to advance the field of aptamer science and technology.
Charles	Sinclair	Vice President, Translation Sciences	Pioneering Medicines	https://proventainternational.com/wp-content/uploads/2025/10/Charles-Sinclair.jpg
Christina	Ansted	Senior Managing Partner	RCP Venture Capital	https://proventainternational.com/wp-content/uploads/2025/08/Christina-Ansted.jpg
Dan	Rozelle	Vice President, Data Analytics	Rancho Biosciences	https://proventainternational.com/wp-content/uploads/2025/10/Dan-Rozelle.jpg
David	Sherris	CEO	Attivare Therapeutics	https://proventainternational.com/wp-content/uploads/2020/01/David-Sherris-1.jpg	Session – Next Generation OV and New Combinational Approaches for Treatment of Solid Tumors Dr. Sherris has over 30 years’ experience in translational medicine involving basic research, pharmaceutics and diagnostics. Dr. Sherris has been a successful serial entrepreneur developing biotechnology companies from the ground up, devising corporate strategy, enacting programs and carrying companies through funding and acquisition. Dr. Sherris prides himself as a “roll up your sleeves” CEO, entrepreneur, business development officer, drug developer and scientist, not simply a delegator. Dr. Sherris has worked with venture capital companies where he has both advised and raised finances for biotech companies. Dr. Sherris has been employed by pharmaceutical and biotechnology companies to manage external (academic groups and contract research organizations) and internal (directly manage, augment and expand internal scientific programs) research and development. Dr. Sherris has been a frequently invited guest speaker at biopharmaceutical business and scientific conferences, a published author and holder of patents in a wide range of therapeutic areas including oncology, ophthalmology, dermatology, neurology, gene therapy and infectious disease. Dr. Sherris has held positions of increasing responsibility in public and private companies. Dr. Sherris has developed drugs from the bench to the clinic, partnered technologies to pharmaceutical companies and raised capital for companies at the triple digit million dollar levels.
Diane	Joseph-McCarthy	Executive Director, Bioengineering Technology & Entrepreneurship Center	Boston University	https://proventainternational.com/wp-content/uploads/2022/07/Diane-Joseph-McCarthy.jpg	Diane Joseph-McCarthy is the Executive Director of the Bioengineering Technology & Entrepreneurship Center and Professor of the Practice in Biomedical Engineering at Boston University. Prior to that, she was a senior life science executive with over 20 years of drug discovery, development, and leadership experience. She was SVP of Discovery & Early Development at EnBiotix, a bioengineering company focused on respiratory and rare disease. She was an Associate Director at AstraZeneca, where she led a global team and task forces to transform Infection’s early portfolio. At Wyeth, she held positions of increasing responsibility. Diane received her PhD from MIT and was a postdoctoral fellow at Harvard University/Harvard Medical School.
Eric	Ma	Senior Principal Data Scientist	Moderna	https://proventainternational.com/wp-content/uploads/2025/10/Eric-Ma.jpg
Fatemeh	Mojtabai	Founder and CEO	Novatarg Theranostics	https://proventainternational.com/wp-content/uploads/2025/09/Fatemeh-Mojtabai.jpg
Govinda	Bhisetti	Vice President and Head of Computational Chemistry	Cellarity	https://proventainternational.com/wp-content/uploads/2020/08/Govinda-Bhisetti-1.jpg	Govinda Bhisetti got his Ph.D. from the Indian I at Vertex Pharmaceuticals Inc. in 1990 and worked in the Computational Sciences department for 22+ yenstitute of Science, Bangalore, in 1986. He joined the Scripps Research Institute in La Jolla, CA, as a postdoctoral fellow in 1987. His work at Scripps involved the use of Cray XMP supercomputers to simulate protein-ligand interactions and design novel inhibitors. From there, he went to workars, where he led molecular modeling and drug design efforts on several drug discovery projects. His research at Vertex led to the discovery of three FDA- approved drugs: two AIDS drugs, Agenerase (amprenavir) and Lexiva (fosamprenavir), and one hepatitis C drug, Incivek (Telaprevir). He is a co-inventor of these drugs and has been named an inventor on 26 patents. He published 72 research papers, including review articles and book chapters.
Huseyin	Mehmet	Executive Director, New Ventures	University of Massachusetts Medical School	https://proventainternational.com/wp-content/uploads/2023/07/Huseyin-Mehmet.jpg	Huseyin Mehmet is a drug hunter and research scientist with >35 years’ experience in basic and clinical academic research and in pharmaceutical / biotechnology drug discovery. He received his PhD from the Medical Research Council in the UJ and went on to work at University College London, the Imperial Cancer Research Fund (now Cancer Research UK), Cold Spring Harbor Lab, USA and then took a faculty position at Imperial College School of Medicine. There his work focused on cerebral hypoxic ischemic injury in neonates and he was part of the team that developed mild hypothermia for the treatment of birth asphyxia. In 2006 Huseyin left the UK to join Merck and Co, in the USA. He worked in biomarker discovery, target identification and several drug discovery programs up to clinical candidate selection. For the next few years, he took on roles with increasing responsibility in several biotech companies and also consulted for a number of start-up companies working with prominent VC firms (e.g. Atlas Ventures and Versant Ventures). Since 2021, Huseyin has led the New Ventures team in the BRIDGE Innovation and Business Development office at UMass Chan Medical School, where he is responsible for the scientific partnering of intellectual property arising from faculty discoveries.
Julia	Fox	Director	Takeda	https://proventainternational.com/wp-content/uploads/2025/11/Julia-fox-1.jpeg
Lakshmi	Muthuswamy	Senior Director and Head, Computational Biology and Data Science	Blueprint Medicines	https://proventainternational.com/wp-content/uploads/2024/11/Lakshmi-Muthuswamy.jpg
Larry	Mulcahy, Ph.D.	Product Manager, Biologics	Revvity Signals	https://proventainternational.com/wp-content/uploads/2025/10/Larry-Mulcahy.jpg
Lijuan	Jiang	Vice President, DMPK & Bioanalysis	Enanta Pharmaceuticals	https://proventainternational.com/wp-content/uploads/2025/07/Lijuan-Jiang.jpg
Michael	Janes	Co Founder – Chief Revenue Officer	RCP Venture Capital	https://proventainternational.com/wp-content/uploads/2025/10/Michael-Janes.jpg
Mohamed	Kassam	Head, Bioinformatics	Zifo	https://proventainternational.com/wp-content/uploads/2025/07/Mohamed-Kassam.jpg
Nathan	McBride	Chief Information Officer	Xilio Therapeutics, Inc.	https://proventainternational.com/wp-content/uploads/2023/07/Nathan-McBride-1.jpg	Nathan McBride is a healthcare CIO with 25 years of experience leading IT teams in the Life Sciences, an advisory consultant, a DX evangelist, and the author of “Life Sciences IT Survival Guide” and “The Calculus of IT”.
Prasoon	Chaturvedi	Vice President, Head of DMPK	C4 Therapeutics, Inc.	https://proventainternational.com/wp-content/uploads/2022/06/Prasoon-Chaturvedi.jpg	Prasoon Chaturvedi, Ph.D., currently leads the DMPK efforts in the protein degrader space as Vice President, DMPK, at C4 Therapeutics in Watertown, MA. Over the last two decades, Prasoon has worked with numerous cutting-edge technologies to drive drug development endeavors in multiple therapeutic areas including infectious disease, oncology, hematology, cardiovascular, inflammation and rare diseases leading to multiple successful IND, CTA, and NDA filings and has made key DMPK contributions for several marketed drugs including NUZYRA® and ONPATTRO®. Prasoon holds a Ph.D. from IIT, Roorkee (India), and did his post-doctoral training at E.K. Shriver Center of Harvard Medical School, MA.
Prateek	Katti	Investor	Newpath Partners	https://proventainternational.com/wp-content/uploads/2025/09/Prateek-Katti.jpg
Richard	Heidebrecht	Vice President of Research and Development	Glycologix	https://proventainternational.com/wp-content/uploads/2021/02/Richard-Heidebrecht-scaled.jpg	Rich Heidebrecht is currently the Vice President of Research and Development at Glycologix. He started his career at Pfizer and Merck before making a transition to Biotech via the Broad Institute. Rich has gained expertise in medicinal, process and analytical chemistry and has worked on diverse therapeutic modalities such as small molecules, cell therapies, medical devices, and polymers including oligonucleotides. Over the course of his career, Rich has contributed to 35 patent/patent applications, 16 papers, two clinical programs and one marketed drug. Doctor Heidebrecht completed his undergraduate work at Worcester Polytechnic Institute and his graduate work at Indiana University with David R. Williams. His postdoc with Stephen Martin at the University of Texas at Austin rounded out two natural product synthesis projects – one total, one formal.
Shengwen	Zhang	Executive Director	QLD Biotherapeutics	https://proventainternational.com/wp-content/uploads/2025/11/Shengwen-Zhang.jpg
Zev	Wisotsky	Director, Drug Discovery New Modality Solutions	Revvity Signals	https://proventainternational.com/wp-content/uploads/2024/04/Zev-Wisotsky.jpg	Zev Wisotsky is Director of Drug Discovery Informatics at Revvity Signals. His scientific training and research background includes neuroscience, biochemistry, molecular biology and drug discovery. He has spent more than eight years in software in go-to-market teams across industries with a heavy focus on biopharma/biotech R&D.
Winnie	Tam	Scientific Director, Head of Precision Medicine Immunology Translation Research	AbbVie	https://proventainternational.com/wp-content/uploads/2025/10/Winnie-Tam.jpg

Aditya Ambade, Ph.D, Ajita V. Singh, Ph.D, Atli Thorarensen, Bill Jackson, Ph.D, Charles Sinclair, Christina Ansted, Dan Rozelle, David Sherris, Diane Joseph-McCarthy, Eric Ma, Fatemeh Mojtabai, Govinda Bhisetti, Huseyin Mehmet, Julia Fox, Lakshmi Muthuswamy, Larry Mulcahy, Ph.D., Lijuan Jiang, Michael Janes, Mohamed Kassam, Nathan McBride, Prasoon Chaturvedi, Prateek Katti, Richard Heidebrecht, Shengwen Zhang, Zev Wisotsky, Winnie Tam

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

09:00 – 10:00

Roundtable Tracks

Target Identification & Hit Validation
Using Computational Methods to Improve Precision and Efficiency in Lead Optimization and Hit Identification

-Richard Heidebrecht
Vice President of Research and Development
Glycologix

DMPK / ADME Toxicology
Bridging Preclinical Models and Human Safety: Innovations in DMPK and Toxicology (Topic TBC)

-Mohammad Shadid
Vice President, Preclinical and Translational Sciences
Korro Bio

In Vivo and In Vitro Pharmacology
Improving Translational Predictability: Enhancing PK/PD Models, Biomarkers, and Multi- Scale Integration in Preclinical Pharmacology

Data Management, Big Data & Digital Transformation
Accelerating Bioinformatics Pipelines with Next-Generation Data Platforms: Lessons from High-Performance Infrastructure at Scale

Data Integration / AI & ML
Innovating In Silico Drug Design through AI and ML

-Diane Joseph-McCarthy
Executive Director, Bioengineering Technology & Entrepreneurship Center
Boston University

Bioinformatics & Digital Transformation
AI-Powered Bioinformatics: The Engine of Digital Transformation in Biology

-Winnie Tam
Scientific Director, Head of Precision Medicine Immunology Translation Research
AbbVie

Private Equity, Venture Capital & Strategic ESTPartnerships
Early-Stage Science, Late-Stage Discipline: What Today’s Investors Want

-Christina Ansted
Senior Managing Partner
RCP Venture Capital

-Michael Janes
Co Founder – Chief Revenue Officer
RCP Venture Capital

11:10 – 12:10

Roundtable Tracks

Target Identification & Hit Validation
Target Identification and Hit Validation: Bridging Biology and Chemistry

-Ajita V. Singh, Ph.D
Associate Director, Discovery Biology
SAI Life Sciences

SAI LIFE SCIENCES

DMPK / ADME Toxicology
Alternative (non-antibody-based) affinity reagents in therapeutic development

-Bill Jackson, Ph.D
Founder & CEO
Base Pair Biotechnologies, Inc.

Sponsor

In Vivo and In Vitro Pharmacology
Translating Biology: Advances in In Vitro and In Vivo Pharmacology

-Aditya Ambade, Ph.D
Director Business Development Discovery Biology
SAI Life Sciences

SAI LIFE SCIENCES

Data Management, Big Data & Digital Transformation
The Data Integration Crisis in Drug Discovery

-Zev Wisotsky
Director, Drug Discovery New Modality Solutions
Revvity Signals

REVVITY SIGNALS

Data Integration / AI & ML
Beyond the ELN: Turning Data Chaos into Connected Discover

-Larry Mulcahy, Ph.D.
Product Manager, Biologics
Revvity Signals

REVVITY SIGNALS

Bioinformatics & Digital Transformation
Accelerate Insights by Democratizing AI-Ready Data for your Organization

-Dan Rozelle
Vice President, Data Analytics
Rancho Biosciences

RANCHO BIOSCIENCES

Private Equity, Venture Capital & Strategic ESTPartnerships
Strategic Alliances and Investment Strategies: Fueling the Future of Drug Discovery

Sponsor

12:15 – 13:15

Roundtable Tracks

Target Identification & Hit Validation
Unveiling Membrane Protein Dynamics in Native States: Next Generation Structural Tools for Drug Discovery

-Fatemeh Mojtabai
Founder and CEO
Novatarg Theranostics

DMPK / ADME Toxicology
Developments in Predictive Modeling and Metabolic Profiling for Advancing Drug Discovery with DMPK (Topic TBC)

-Prasoon Chaturvedi
Vice President, Head of DMPK
C4 Therapeutics, Inc.

In Vivo and In Vitro Pharmacology
Translating Preclinical Experiments to Clinic Application

-Shengwen Zhang
Executive Director
QLD Biotherapeutics

Data Management, Big Data & Digital Transformation
Hard-Won Lessons, and Questions, Making Laboratory Data Machine Learning Ready

-Eric Ma
Senior Principal Data Scientist
Moderna

Data Integration / AI & ML
AI-Powered Drug Discovery Trends and Challenges in 2025

-Govinda Bhisetti
Vice President and Head of Computational Chemistry
Cellarity

Bioinformatics & Digital Transformation
Towards Transparent and Inclusive Innovation: Balancing the Power of Data Mining and Data Science with the Need for Human-Centric AI

-Julia Fox
Director
Takeda

Private Equity, Venture Capital & Strategic ESTPartnerships
Early-Stage Science, Late-Stage Discipline: What Today’s Investors Want

-Prateek Katti
Investor
Newpath Partners

15:10 – 16:10

Roundtable Tracks

Target Identification & Hit Validation
Turning Novel Biology into Clinical Reality: Integrating Translational Research to Enhance the Success of Emerging Therapeutics

-Charles Sinclair
Vice President, Translation Sciences
Pioneering Medicines

DMPK / ADME Toxicology
Strategies to Optimize ADME Properties in Drug Discovery to Enhance Drug Bioavailability

-Lijuan Jiang
Vice President, DMPK & Bioanalysis
Enanta Pharmaceuticals

In Vivo and In Vitro Pharmacology
Advanced In Vitro Models Enhancing Predictive Accuracy in Drug Discovery

Data Management, Big Data & Digital Transformation
Bridging the Data Divide in Bioinformatics: Innovative Approaches to Data Management and Analysis

Data Integration / AI & ML
Building Robust AI Models for Improved Data Quality and Represent ation in Drug Discovery (Topic TBC)

-Atli Thorarensen
Vice President, Head of Chemistry
Cellarity

Bioinformatics & Digital Transformation
Beyond Buzzwords: What Digital Transformation Really Means in 2025

-Nathan McBride
Chief Information Officer
Xilio Therapeutics, Inc.

Private Equity, Venture Capital & Strategic ESTPartnerships
Private Equity, Venture Capital & Strategic Partnerships

-Huseyin Mehmet
Executive Director, New Ventures
University of Massachusetts Medical School

17:00 – 18:00

Europe

USA East

USA West

Webinars

Dinners & Spotlights

R&D

R&D Boston

Medicinal Chemistry Strategy Meeting East Coast – Boston 2024

&

Strategy Meeting East Coast USA 2025

<img class="lazy" decoding="async" src="data:image/svg+xml,%3Csvg%20xmlns='http://www.w3.org/2000/svg'%20viewBox='0%200%201%201'%3E%3C/svg%3E" data-src="https://proventainternational.com/wp-content/uploads/2020/12/location.png" >Le Méridien Boston Cambridge

Fresh Biology Insights

What makes our strategy meetings unique?

Roundtable Discussions

Unrivalled Networking

Personalised Agenda

Solutions to your Problems

Industry Researched Topics

Senior Decision Makers

Our Facilitators

Aditya Ambade, Ph.D

Ajita V. Singh, Ph.D

Atli Thorarensen

Bill Jackson, Ph.D

Charles Sinclair

Christina Ansted

Dan Rozelle

David Sherris

Diane Joseph-McCarthy

Eric Ma

Fatemeh Mojtabai

Govinda Bhisetti

Huseyin Mehmet

Julia Fox

Lakshmi Muthuswamy

Larry Mulcahy, Ph.D.

Lijuan Jiang

Michael Janes

Mohamed Kassam

Nathan McBride

Prasoon Chaturvedi

Prateek Katti

Richard Heidebrecht

Shengwen Zhang

Zev Wisotsky

Winnie Tam

Our Agenda

See Which Topics Are Discussed at the Strategy Meeting

Breakfast & Registration

Opening Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Refreshment Break

Networking / 1-1 Meetings

Roundtable (Solution)

Roundtable Tracks

SAI LIFE SCIENCES

Sponsor

SAI LIFE SCIENCES

REVVITY SIGNALS

REVVITY SIGNALS

RANCHO BIOSCIENCES

Sponsor

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Networking Lunch

Networking/1-1 Meetings

Afternoon Keynote Presentation

Roundtable ( Pharma/Biotech )

Roundtable Tracks

Afternoon Refreshment Break

Panel Discussion

Drinks & Canapes Reception

Reasons To Attend Our Strategy Meetings

Fully Interactive Format

Senior Decision Makers

Personalised Agendas

Private and Intimate Networking

Our Sponsors

Thought Leaders

Le Méridien Boston Cambridge